Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Exchange Rate Effect (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Exchange Rate Effect for 16 consecutive years, with -$83000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Exchange Rate Effect fell 122.43% to -$83000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $525000.0, a 1212.5% increase, with the full-year FY2024 number at -$140000.0, up 56.25% from a year prior.
  • Exchange Rate Effect was -$83000.0 for Q3 2025 at Harvard Bioscience, down from $632000.0 in the prior quarter.
  • In the past five years, Exchange Rate Effect ranged from a high of $632000.0 in Q2 2025 to a low of -$363000.0 in Q4 2024.
  • A 5-year average of $12052.6 and a median of -$25000.0 in 2022 define the central range for Exchange Rate Effect.
  • Peak YoY movement for Exchange Rate Effect: crashed 708.33% in 2021, then soared 15700.0% in 2025.
  • Harvard Bioscience's Exchange Rate Effect stood at -$80000.0 in 2021, then plummeted by 337.5% to -$350000.0 in 2022, then skyrocketed by 47.71% to -$183000.0 in 2023, then tumbled by 98.36% to -$363000.0 in 2024, then skyrocketed by 77.13% to -$83000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Exchange Rate Effect are -$83000.0 (Q3 2025), $632000.0 (Q2 2025), and $339000.0 (Q1 2025).